Dublin, Ireland-based Horizon Therapeutics plc, previously known as Horizon Pharma plc, is a biopharmaceutical focused on making drugs in arthritis, pain, inflammatory and orphan diseases areas. Horizon Therapeutics (Horizon) was formed in September 2014, after Horizon, and Vidara acquired Ireland-based privately held specialty pharmaceutical company, Vidara Therapeutics International Ltd. through a reverse merger. On May 2, 2019, shareholders approved the change of the company’s name to Horizon Therapeutics. This move caters to the company’s long-term strategy to develop and commercialize innovative medicines addressing rare diseases, which currently have very few effective treatment options.
Horizon has been actively pursuing acquisitions to expand and diversify its portfolio. While the company acquired rights to Vimovo (November 2013) and Pennsaid 2% (October 2014) in the United States from AstraZeneca and Nuvo Research Inc. respectively, it acquired certain rights (in the United States, Canada, and Japan) to Actimmune through the September 2014 Vidara merger. Horizon acquired the global rights to Actimmune from Boehringer Ingelheim in June 2017. Ravicti and Buphenyl became part of company’s portfolio through the May 2015 Hyperion Therapeutics acquisition, and Migergot and Krystexxa (pegloticase injection) became part of the company’s portfolio through the January 2016 Crealta Holdings acquisition. In October 2016, Horizon acquired Raptor and added Procysbi and Quinsair to its portfolio.
In January 2020, the FDA granted approval to Tepezza (teprotumumab) as a treatment for patients with thyroid eye disease (TED).
The company generally reports its results under two operating segments —the Orphan and Rheumatology (now renamed as the Orphan segment), and the Inflammation segment.
Sales in 2020 came in at $2.2 billion, up 69.2% year over year. Sales from the Orphan segment came in at $1.8 billion. Sales from the Inflammation segment were $412.7 million.